{"organizations": [], "uuid": "86e4a002d239effdaa9bd282edcbf1015ff2e866", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-mercks-keytruda-approved-in-japan/brief-mercks-keytruda-approved-in-japan-for-use-in-the-treatment-of-patients-with-urothelial-carcinoma-idUSFWN1OX05F", "country": "US", "domain_rank": 408, "title": "BRIEF-Merck’s Keytruda Approved In Japan For Use In The Treatment Of Patients With Urothelial Carcinoma", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-02T14:09:00.000+02:00", "replies_count": 0, "uuid": "86e4a002d239effdaa9bd282edcbf1015ff2e866"}, "author": "", "url": "https://www.reuters.com/article/brief-mercks-keytruda-approved-in-japan/brief-mercks-keytruda-approved-in-japan-for-use-in-the-treatment-of-patients-with-urothelial-carcinoma-idUSFWN1OX05F", "ord_in_thread": 0, "title": "BRIEF-Merck’s Keytruda Approved In Japan For Use In The Treatment Of Patients With Urothelial Carcinoma", "locations": [], "entities": {"persons": [], "locations": [{"name": "japan", "sentiment": "none"}, {"name": "japan", "sentiment": "none"}], "organizations": [{"name": "reuters) - merck & co inc", "sentiment": "none"}, {"name": "urothelial carcinoma reuters", "sentiment": "none"}, {"name": "taiho pharmaceutical co ltd", "sentiment": "none"}, {"name": "merck & co inc", "sentiment": "none"}, {"name": "keytruda", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 09 PM / in 12 minutes BRIEF-Merck’s Keytruda Approved In Japan For Use In The Treatment Of Patients With Urothelial Carcinoma Reuters Staff 1 Min Read \nJan 2 (Reuters) - Merck & Co Inc: \n* MERCK’S KEYTRUDA® (PEMBROLIZUMAB) APPROVED IN JAPAN FOR USE IN THE TREATMENT OF PATIENTS WITH UROTHELIAL CARCINOMA THAT IS UNRESECTABLE WITH RADICAL SURGERY WHO HAVE PROGRESSED FOLLOWING CANCER CHEMOTHERAPY \n* MERCK & CO INC - WILL MARKET KEYTRUDA IN JAPAN AND WILL PROMOTE IT WITH TAIHO PHARMACEUTICAL CO LTD \n* MERCK & CO INC - WITH THE APPROVAL, KEYTRUDA IS NOW INDICATED FOR USE IN FOUR TYPES OF CANCER IN JAPAN  ", "external_links": [], "published": "2018-01-02T14:09:00.000+02:00", "crawled": "2018-01-02T14:23:12.010+02:00", "highlightTitle": ""}